Related documents, manuals and ebooks about What Is Persidis Disease
Andreas Persidis cofounded Biovista in 1996, a biotech which already has two repurposed drug candidates for treating progressive multiple sclerosis. ... By simply identifying a different disease that can be treated with an existing drug, ...
cause disease but develop protective immunity against various species of Leishmania. ... Aris Persidis, Ph.D., President, Biovista, Inc. 8:30 Repurposing Kinase-Targeted Medicinal Chemistry for Neglected Tropical Disease Drug Discovery
2 Challenges in the biopharma sector Repositioning as a driver for value creation Industrial Technologies 2014 – Athens 9-11 April Dr. Andreas Persidis
to identify novel therapies for any neglected Disease Aris Persidis, Ph.D., President, Biovista, Inc. Mechanism of Action (MoA) can be used to map any drug against any disease and any adverse event. A systematic effort to identify novel
than any other communicable disease except tuberculosis (Persidis, 2000). P. vivax infections account for more than half of the cases of malaria outside Africa and approximately 10% of the malaria in Africa. It is also prevalent in many regions of Asia and
Human Disease, Models of Immune Processes and Transgenic Tools. Data on mutant strains includes detailed information on ... Pasparakis M, Persidis A, Pfeffer K, Radbruch A, Rajewsky K, Ricciardi-Castagnoli P, Romagne F, Schneider P, Tocchini – Valentini G, Tschopp J, Van den Broek M ...
New Life for Old Drugs Published on Drug Discovery & Development (http://www.dddmag.com) potential indications that may be of interest to the company,” says Aris Persidis,
Group of parasites Examples Common name Clade Host Disease symptoms GI/livestock Haemonchus contortus Barber pole worm V Sheep and goat Anemia, diarrhea, lethargy, death ... (Persidis, 1999; Prasad et al., 2002; Moye-Rowley, 2003; Prasad and Kapoor, 2004; Sipos and Kuchler, 2006;
Persidis, Biotechnology in a Snapshot, 18 NATURE BIOTECHNOLOGY IT2 (2000) (Industry T rends Supplement). ... disease group such as the Framingham heart study patients, or even the population of a Iceland. In fact, ...
Andreas Persidis BIOVISTA Klaus Rajewsky Center for Blood Research Inc. Jurg Tschopp University of Lausanne Glauco Tocchini-Valentini CNR Andreas Radbruch ... ¾Disease phenotype to gene function through disease sensitized mutagenesis screens (ENU, transposon, ...
Author:%% Dr.%Andreas%Persidis% % % CEO,%BiovistaInc.% % Doc.%Ref.:%% BVAEPP/14/1% % % April%2014% % What!Role!forSystematicDrugRepositioning?! ! !! Doc.!Ref.:!BVA=PP/14/1!! ! ! ©2014Biovista.AllRightsreserved. !! 1!
cancer or other bladder disease (Atala 2000). Treat - ments ... Persidis 1999). Scaffolds prepared via tissue engineering approach plays important role for bladder disease treatment, which have adjustable properties such as mechanical, elasticity, and ...
agriculture, with concomitant increases in incomes, is needed to raise food-purchasing power and to reduce poverty. Poor people’s links to the land are critical for
By Dr Aris Persidis Drug Discovery World Spring 2011 9 Drug Development The benefits of ... systematic evaluation of any drug or mechanism of action against any disease or adverse event. Drug repositioning_Layout 1 16/03/2011 13:54 Page 9. of their originally-targeted indications, can lever-
structure/function annotations, disease cor-relations, population variations, and just about every piece of relevant information that is being gathered by life science, all entered into massive databases. Bioinformatics is the computer-assisted
58–63; Aris Persidis, “Bioinformatics,” Nature Biotechnology17 (1999): ... (patient-speciﬁc disease proﬁling). Bio-media is only an interest in digitization inasmuch as the digital transforms what is understood as biological. In short, the body you
Many people worldwide suffer from bone defects due to trauma or disease. About 5-10% of football injury-related bone fractures, in addition to bone tumor resection and massive ... Persidis, A.(1999). Tissue engineering. Nat Biotechnol, Vol. 17, pp.(508-510)
least a subset of proteins (Geisow 1998; Persidis 1998). In addition, various methods are available for elucidat-ing physical interactions between proteins in live cells ... ing disease associated genes. However, these strategies are too time consuming for efficient genome-wide in-
a gloomy “information overload in biology” (A. Persidis 1999). The Noah’s Ark to biologists lies in the land of bioinformatics, ... disease information in the form of cross-linked encyclopedic library cards. However, few databases
Most of these cases are diagnosed in the late stages of the disease where a combination of cost-effectiveness and affordable interventions is lacking. Other risk factors associated directly with breast cancer include hereditary, ... (Persidis, 1999). Given the
Cures Within Reach 2011-12 Annual Report Contents 1. Mission and Vision 2. 2012 Leadership 3. President’s Letter ... Through this research sourcing process and our partnerships with smaller, disease specific organizations, we ...
Aris Persidis, Ph.D., President, Biovista Stephen Wong ... array of drug-like properties) there is a rationale for employing high quality (i.e. in vivo models of disease) forms of phenotypic screening ... Drug repositioning oﬀers the potential to create value for patients in a quicker time ...
understanding the contribution of complex biological pathways to human pathophysiology and disease. In the post-genomic era, the concept ... A. Persidis, S. Deftereos, A. Persidis, Systems literature analysis, Pharmacogenomics 5 (2004) 943–947.
of human disease, and as new devices are introduced in environmental, food, livestock and agricultural testing. Larger samples of tests will be able to be compared from any laboratory worldwide, whilst advances in the availability of information on the
ing individualized medicine (Cohen, 1997; Persidis, 1998). Pharma-cogenomics, which relates genomic function to molecular pharmacol-ogy, promises to redefine basic notions in drug discovery and disease management. Some companies are devoting their efforts to establish-
Plasmodium falciparum, is considered an inflammatory disease. Objective: We determined P-glycoprotein expression at protein levels in human CM brain capillaries. ... Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999; 17:94-5. 3.
Disease Preg n acy/L tion Adapted from ICH E5, 1998: http://www.fda.gov/cder/guidance/2293fnl.pdf Extrinsic factors ... <Survey via Biovista; courtesy: Aris Persidis> 12 (Huang, S-M, Advisory committee, http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4248s1-index.htm)
disease for decades, but the field of proteomics offers a more global perspective. Because such analysis embraces ... PERSIDIS, A. (2001). Proteomics. Nat. Biotechnol, 18,Suppl, IT45–IT46. PETRICOIN, E.F., ARDEKANI, A.M., HITT, B.A., et al.
disease. Considering the characteristics of this study, we cannot state that PDT improves final VA or prevents long-term recurrences. ... Persidis E, Conway MD, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse reti-
the target (Persidis 1998, Sittampalam et al. 1997). ... ing for ion channels and comment on the opportunities for improvements ... diac disease states while retaining target selectivity and speciﬁc modes of action to minimize side effects.
Aris Persidis 7. Predicting the Polypharmacology of Drugs: ... Repurposing Drugs for Tropical Disease: Case Studies and Open-Source Screening Initiatives 347 Curtis R. Chong 12. Drug Repositioning Efforts by Nonprofit Foundations 389 13.
Medical Expert Systems 27 Medical Expert Systems: An Overview Aris Persidis Department of Medicine, University of Cambridge Clinical School, and
Persidis (2000) describes data mining as the nontrivial extraction of implicit, previously unknown, and potentially useful information from data. ... disease diabetes and Chapter 2.7 describes the gene expression data used for this project.
Disease Overview & Treatment Options including treatment strategies & individualized strategies ... For further information, please contact Aris Persidis, [email protected] , 434-242-6514 . Title: Microsoft Word - Biovista_Meta Reviews_6Mar08.doc
large role on disease response? Ethical Considerations Will people with rare genetic profiles simply ... Persidis A. “Pharmacogenomics and diagnostics.” Nat Biotechnol. 1998 Aug;16(8):791-2. References 16) Housman D, Ledley FD. “Why pharmacogenomics?
predisposition to disease and developing cures for the NEW HORIZONS Future Challenges of Pharmacogenomics in Clinical Practice V. Bansal, V. Kumar*, B. Medhi. ... Persidis A. Pharmacogenomics and diagnostics. Nature Biotechnology1998;16:791-92. 8.
potential (Persidis 1999). Successful tissue engineering requires the coordi-nation of three elements: the ... (1999) Destructive periodontal disease in adults 30 years of age and older in the United States, 1988–1994. Journal of Periodontology
Malaria is today a disease of poverty and undeveloped countries but it remains an important health problem globally. In the last decade, ... Persidis, A (2000). Malaria. Nature Biotechnology 18: 111-112. Phillipson, J.D (1991).
THE ANTIMALARIAL ACTIVITY OF THE CRUDE ORGANIC EXTRACTS OF FOUR COMMONLY USED NIGERIAN MEDICINAL PLANTS. ... The limited number of such drugs has led to increasing difficulties in the development of antimalarial drug policy and adequate disease management ... (Persidis, 2000).
the possibility of disease transmission between the donor and ... Hazlehurst, 2004; Lysaght and Reyes, 2001; Persidis, 1999). A current major technical and engineering challenge is to provide suitable TE scaffolds (Grifﬁth and Naughton, 2002).
identifying proteins that may correlate to various disease states.1 The rapid acceleration of research in the area of proteomics requires the development of new ... Persidis, A. Nat. Biotechnol. 1998, 16, 393-394. (2) Henzel, W. J.; Billeci, T. M.; Stults, J. T., Wong, S. C.; Grimley ...
odical understanding of a disease’s underlying mechanisms and helps monitoring areas where scientiﬁc advances are likely to create new therapeutic opportunities . ... 9 Persidis, A. (2011) Drug Repositioning: a union of patient interests,
disease management companies, advocacy or-ganizations, regulators, or the government. ... ARIS PERSIDIS isPr edn tofB v a pr iv ae l y h db oc ng m f s n ov elu sf rx itg da p h f ctsu i ng h rma o.F nf or mat, vsb .c 1.Payers and society are demanding more
understand the molecular and cellular basis of the human disease. The research teams integrated in the MUGEN Network have proven records of excellence in the network’s various research sectors and ... Biovista EL Biovista Dr. Andreas Persidis ...
• Member , Andreas Persidis, CEO, Biovista. HBio Members. BioAnalytica-GenoType S.A. Offering advanced molecular and cytogenetic analyses ... humanized disease animal models. Regulon S.A. Discovery and development of low-toxicity anticancer
sate the loss of function in tissues of the human body which is due to disease, trauma or congenital defects. ... Persidis 2000). The primary goal of all approaches in tissue engineering is the restoration of function through the delivery of living elements which become integrated into the
of individual patient’s predisposition to a specific disease [3,4]. As with any surpassing technology, what alternative functions are bestowed to the replaced one? Previous technological generations have always been relegated to bulk bench top work or outright eliminated.
on Pasteuria penetrans: PERSIDIS LAY, MANOUSIS , , BISHO ANPD ELLAR 613 Adhesion plaques of fibroblasts, talin an FELTKAMPd vinculin, PIJNENBUR: ANDG ROOS 579 Adiantum protonemata, PPB and cell plate formation MINEYUKI: , MURATA AND WADA 551 Aging
Tissue Engineering – A Professional Engineering Perspective ... (Persidis, 2000). The Canadian experience ... diagnosis, and treatment of disease, for patient rehabilitation, and for improving health (NIH Working
Persidis. (2010) Dimebon Ameliorates Disease Severity in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) Animal Model of Progressive Multiple Sclerosis (MS). American Neurological Association, 135th Annual Meeting, 12-15 September, San Fransisco